Back to Search
Start Over
Expression levels of HLA-DR in acute myeloid leukemia: implications for antigenicity and clinical outcome.
- Source :
- Leukemia & Lymphoma; Aug2021, Vol. 62 Issue 8, p1907-1919, 13p
- Publication Year :
- 2021
-
Abstract
- Low human leukocyte antigen (HLA)-DR expression might compromise CD4<superscript>+</superscript> T-cell-mediated anti-tumor immunity. Its immunological and clinical significance however remain undefined in non-promyelocytic acute myeloid leukemia (AML). Taking advantage of mass spectrometry-based immunopeptidome analysis of primary AML samples (n = 31), we studied the implications of low HLA-DR expression for antigen presentation and analyzed its association with disease characteristics and survival within a cohort of 399 AML patients. Remarkably, overall HLA-DR/DQ immunopeptidome diversity was preserved in AML with low HLA-DR expression (HLA-DR<superscript>low</superscript> AML) and was associated with a shift in HLA-DR/DQ allotype abundances (HLA-DQ to HLA-DR/DQ ligand ratio 0.36 vs 0.19 in HLA-DR<superscript>low</superscript> and HLA-DR<superscript>high</superscript> patients, respectively). Consistent with unimpaired antigenicity, survival was similar in HLA-DR<superscript>low</superscript> and HLA-DR<superscript>high</superscript> patients. Demonstrating for the first time that overall HLA-DR/DQ antigen presentation is preserved in HLA-DR<superscript>low</superscript> AML, our findings provide a rationale for the non-inferior outcome observed in HLA-DR<superscript>low</superscript> AML patients. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 10428194
- Volume :
- 62
- Issue :
- 8
- Database :
- Complementary Index
- Journal :
- Leukemia & Lymphoma
- Publication Type :
- Academic Journal
- Accession number :
- 151831376
- Full Text :
- https://doi.org/10.1080/10428194.2021.1885659